Interleukin-10 Serum Levels after Vaccination with In Vivo Prepared Toxoplasma gondii Excreted/Secreted Antigens

Abdollahi, Seyed Hossein; Ayoobi, Fateme; Khorramdelazad, Hossein; Hassanshahi, Gholamhossein; Ahmadabadi, Behzad Nasiri; Rezayati, Mohammad Taghi; Ravary, Ali; Shamsizadeh, Ali; Arababadi, Mohammad Kazemi

doi:10.5001/omj.2013.29

Cited by 16 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study observed significantly increased levels of IFN-γ and IL-2 in pVAX-ROP38 immunized mice. IL-4 can up-regulate MHC class II production [ 36 ], and IL-10 inhibits B and T lymphocytes proliferation and suppresses human macrophages activity in vivo [ 37 – 39 ] . The sharply increased levels of IFN-γ and IL-2 and the decreased levels of IL-4 and IL-10 cytokines in mice immunized with pVAX-ROP38 demonstrated that a strongly Th1-type immune response was elicited.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of immuno-efficacy of a novel DNA vaccine encoding Toxoplasma gondiirhoptry protein 38 (TgROP38) against chronic toxoplasmosis in a murine model

Zhang

Tan

et al. 2014

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundToxoplasma gondii is an obligate intracellular parasite which can infect almost all mammalian animals, leading to toxoplasmosis. T. gondii rhoptry protein 38 (TgROP38) is an active rhoptry protein kinase which is involved in the inhibitory effect on host cell transcription by down-regulating the MAPK signaling track.MethodsTgROP38 gene was amplified and inserted into eukaryotic vector pVAX I and formed the DNA vaccine pVAX-ROP38. Mice in the experimental group were intramuscularly immunized with pVAX-ROP38 and those injected with pVAX I, PBS or nothing were treated as controls. After three injections at two week intervals, all mouse groups were challenged intraperitoneally with 1000 tachyzoites of the virulent T. gondii RH strain (Type I, ToxoDB #10) and 10 cysts of the PRU strain (Type II, ToxoDB #1), respectively.ResultsMice inoculated with pVAX-ROP38 vaccine had a higher level of IgG antibodies (P < 0.01) and T lymphoproliferative response. The high ratio of IgG2a/IgG1 and the increasing levels of IFN-γ and IL-2 (P < 0.05) indicated an activated Th1 cell-mediated immune responses. Furthermore, the CD4+ and CD8+ proportions in vaccinated mice were also increased significantly compared with that in mice of the three control groups (P < 0.01). In the model of acute infection, the average survival time of mice in the pVAX-ROP38 group (8.1 days ± 0.75) was no statistically different compared to that in the PBS, pVAX I and blank control groups which died within 7 days. However, in the model of chronic infection, the brain cyst reduction in the pVAX-ROP38 group reached 76.6%, compared to controls (P < 0.01).ConclusionsThe present study revealed that the pVAX-ROP38 vaccine could elicit strong humoral and cell immunity response against chronic T. gondii infection in mice, resulting in the reduction of the brain cyst formation effectively, which suggests that TgROP38 is a desirable vaccine candidate against chronic T. gondii infection.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2334-14-525) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of immuno-efficacy of a novel DNA vaccine encoding Toxoplasma gondiirhoptry protein 38 (TgROP38) against chronic toxoplasmosis in a murine model

Zhang

Tan

et al. 2014

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…Recently, Abdollahi et al showed that although serum levels of IL-10 were not changed at the early phases, they were elevated at the end phases (14 and 28 days) of vaccination with T. gondii E/SA [54]. The levels of IL-10 in mice immunised with rTgACT were increased 2 weeks after immunization in present study, which was in line with the result of Abdollahi et al [54]. However, above studies have not to discuss why the changes of IL-10 appeared or not, so this is a interesting question requiring further discussion.…”

Section: Discussionmentioning

confidence: 99%

Intranasal Immunisation with Recombinant Toxoplasma gondii Actin Partly Protects Mice against Toxoplasmosis

et al. 2013

View full text Add to dashboard Cite

Toxoplasma gondii is a ubiquitous protozoan intracellular parasite, the causative agent of toxoplasmosis, and a worldwide zoonosis for which an effective vaccine is needed. Actin is a highly conserved microfilament protein that plays an important role in the invasion of host cells by T. gondii. This study investigated the immune responses elicited by BALB/c mice after nasal immunisation with a recombinant T. gondii actin (rTgACT) and the subsequent protection against chronic and lethal T. gondii infections. We evaluated the systemic response by proliferation, cytokine and antibody measurements, and we assessed the mucosal response by examining the levels of TgACT-specific secretory IgA (SIgA) in nasal, vaginal and intestinal washes. Parasite load was assessed in the liver and brain, and the survival of mice challenged with a virulent strain was determined. The results showed that the mice immunised with rTgACT developed high levels of specific anti-rTgACT IgG titres and a mixed IgG1/IgG2a response with a predominance of IgG2a. The systemic immune response was associated with increased production of Th1 (IFN-γ and IL-2), Th2 (IL-4) and Treg (IL-10) cytokines, indicating that not only Th1-type response was induced, but also Th2- and Treg-types responses were induced, and the splenocyte stimulation index (SI) was increased in the mice immunised with rTgACT. Nasal immunisation with rTgACT led to strong mucosal immune responses, as seen by the increased secretion of SIgA in nasal, vaginal and intestinal washes. The vaccinated mice displayed significant protection against lethal infection with the virulent RH strain (survival increased by 50%), while the mice chronically infected with RH exhibited lower liver and brain parasite loads (60.05% and 49.75%, respectively) than the controls. Our data demonstrate, for the first time, that actin triggers a strong systemic and mucosal response against T. gondii. Therefore, actin may be a promising vaccine candidate against toxoplasmosis.

show abstract

“…T-lymphocytes in response to vaccination by single parasite peptide (AS15), which is one of the constituent of ESA. Vaccination with ESA showed no increase of IL-10 serum levels at the early phases, this cytokine when increase inhibits the proliferation of B and T lymphocytes and suppresses the killing of T. gondii by human macrophages (Abdollahi et al 2013).…”

Section: Discussionmentioning

confidence: 99%

A comparative study between excretory/secretory and autoclaved vaccines against RH strain of Toxoplasma gondii in murine models

et al. 2013

View full text Add to dashboard Cite

Toxoplasma gondii is an obligate intracellular protozoan that has a major importance in public health, in addition to veterinary medicine. Therefore, the development of an effective vaccine for controlling toxoplasmosis is an important goal. Excretory/secretory antigens (ESA), were previously identified as potential vaccine candidates, proved to play important roles in the pathogenesis and immune escape of the parasite. In addition, autoclaved Toxoplasma vaccine (ATV) is a special type of killed vaccine, recently characterized. The aim of the present work was, to compare between excretory/secretory and ATV against RH strain of T. gondii in mice based on; parasitological and histopathological levels. Tachyzoites were harvested from peritoneal exudates of infected mice and were used for challenge infection and vaccine preparation. BCG was used as an adjuvant. Mice were allocated equally into five groups; they were vaccinated intradermally over the sternum. The results of this study showed that the survival time after challenge, extended up to 16 days in ESA vaccinated group and up to 15 days in autoclaved Toxoplasma vaccinated group. ESA vaccinated group exhibited a profound decrease in parasite load following parasite challenge with a higher percentage of reduction in parasite count in all examined organs than the autoclaved Toxoplasma vaccinated group. The histopathological picture of the liver in both immunized groups, revealed marked reduction in the pathological changes observed as compared to controls, especially in ESA vaccinated group. It was concluded that vaccination with ESA showed more promising results versus ATV, as demonstrated by the survival rate of vaccinated mice, tachyzoites count and histopathological examination.

show abstract

Interleukin-10 Serum Levels after Vaccination with In Vivo Prepared Toxoplasma gondii Excreted/Secreted Antigens

Abstract: Based on these and our previous results, it can be concluded that in vivo prepared T. gondii E/SA could be considered as a good candidate for animal vaccination.

Cited by 16 publications

References 20 publications

Evaluation of immuno-efficacy of a novel DNA vaccine encoding Toxoplasma gondiirhoptry protein 38 (TgROP38) against chronic toxoplasmosis in a murine model

Evaluation of immuno-efficacy of a novel DNA vaccine encoding Toxoplasma gondiirhoptry protein 38 (TgROP38) against chronic toxoplasmosis in a murine model

Intranasal Immunisation with Recombinant Toxoplasma gondii Actin Partly Protects Mice against Toxoplasmosis

A comparative study between excretory/secretory and autoclaved vaccines against RH strain of Toxoplasma gondii in murine models

Contact Info

Product

Resources

About